Merck Millipore Announces Partnership with NIH Consortium
News Oct 16, 2012
Merck Millipore has announced that Merck Millipore has entered into an agreement with an academic consortium funded by the NIH, to distribute more than 140 peer-validated neuroscience-specific monoclonal antibodies through its worldwide network.
This set of antibodies has been specifically requested by academic researchers for key targets in neuroscience research.
The antibodies have been submitted and vetted through a formal process, led by academicians, and have been determined to be valuable and worthy of development in light of today's neuroscience research priorities.
These key targets in neurodevelopment, metabolism, oxidative stress, synaptic function, neurodegeneration and disease have been tested in multiple species, including genetic knockout mice.
In addition, the antibodies have been independently peer-reviewed and research validated prior to being made available through Merck Millipore.
"Merck Millipore's objective is to help our customers advance the study of neuroscience," notes John Sweeney, Executive Vice President, Merck Millipore Bioscience Division.
Sweeney continued, "We are excited about this partnership with the NIH consortium, one of the largest sources of medical research funding in the world. This partnership will enable us to provide access to this novel range of neuroscience antibodies in addition to others, allowing us to provide cutting edge tools for researchers focused on metabolism, oxidative stress, synaptic function, neurodegeneration and more."
Merck Millipore is currently one of the top antibody manufacturers worldwide, with the majority of antibodies licensed and manufactured in California.
A significant number of Merck Millipore's antibody portfolio and technical expertise includes antibodies and research staff from Chemicon®, Upstate®, Linco® and Calbiochem®, which were acquired by the company over the past several years.
With its primary focus on quality and stringent validation, Merck Millipore's antibodies are backed by its commitment to quality and a unique performance guarantee.
In addition to developing and testing a wide range of antibodies, Merck Millipore has research and development teams dedicated to expanding its significant portfolio of immunotechnologies including its Multiplex, Elisas, and other cell-based assays, as well as novel flow cytometry, guava easycyte®, Amnis® and Muse® products for cell analysis and imaging.
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE
What Does the Future of Vaccines and Immunotherapy Look Like?News
Innovative biomaterials could enhance vaccines against HIV and other infectious diseases and immunotherapies for patients with cancer or dampen responses in autoimmune disorders, allergies and transplanted organ recipients. A review of these efforts was recently released.READ MORE
CMC Biologics Announces Development and Manufacturing Agreement with Harpoon TherapeuticsNews
Companies have entered into agreement for the development and manufacturing of three TriTAC molecules for the treatment of cancers.READ MORE